Skip to main content

Advertisement

SpringerLink
Log in

Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care

  • Letters of Biomedical and Clinical Research
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Glintborg B, Loft AG, Omerovic E et al (2019) To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 77:192–200

    Article  Google Scholar 

  2. Tweehuysen L, Huiskes VJB, van de Bemt BJF et al (2018) Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4. Arthritis Rheum 70:1408–1418

    Article  CAS  Google Scholar 

  3. Glintborg B, Sorensen IJ, Loft AG et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76:1426–1431

    Article  CAS  Google Scholar 

  4. Germain V, Scherlinger M, Barnetche T, Schaeverbeke T, Federation Hospitalouniversitaire A (2020) Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Ann Rheum Dis 79(1):e11. https://doi.org/10.1136/annrheumdis-2018-214374

    Article  PubMed  Google Scholar 

  5. Tweehuysen L, van den Bemt BJF, van Ingen IL et al (2018) Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheum 70:60–68

    Article  CAS  Google Scholar 

  6. Scherlinger M, Germain V, Labadie C et al (2017) Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Jt Bone Spine 85:561–567

    Article  Google Scholar 

  7. Rezk MF, Pieper B (2018) To see or NOsee: the debate on the nocebo effect and optimizing the use of biosimilars. Adv Ther 35:749–753

    Article  Google Scholar 

  8. Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Charland K, Woolcott J, Jones H (2018) Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data. Clin Rheumatol 37:2351–2360

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Unit, “Villa Sofia – Cervello” Hospital, via del Fante, 90144, Palermo, Italy

    Giuseppe Provenzano, Chiara Arcuri & Maria Concetta Miceli

Authors
  1. Giuseppe Provenzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Arcuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Concetta Miceli
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Provenzano made substantial contributions to the analysis and interpretation of data and drafted the manuscript. Arcuri participated in the collection and analysis of data and has been involved in drafting the manuscript. Miceli participated in the collection and analysis of data.

Corresponding author

Correspondence to Giuseppe Provenzano.

Ethics declarations

Competing interests

Giuseppe Provenzano served as advisory board member and/or received lecture grants from AbbVie, Biogen, BMS, Grunenthal, Lilly, MSD, Roche, Sandoz, Sanofi and UCB. Chiara Arcuri served as advisory board member and/or received lecture grants from AbbVie, BMS, Celgene, Novartis and Roche. Maria Concetta Miceli served as advisory board member and/or received lecture grants from BMS, Lilly, Novartis, Roche, Sanofi and UCB.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Provenzano, G., Arcuri, C. & Miceli, M.C. Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care. Clin Rheumatol 40, 425–427 (2021). https://doi.org/10.1007/s10067-020-05327-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05327-6

Keywords

Search

Navigation